Hansoh Acquires Cytopenia Therapy in Agreement Worth up to $190 Million
publication date: Dec 13, 2021
Jiangsu Hansoh Pharma acquired China rights to a novel cytopenia therapy from Keros Therapeutics in an $190 million agreement. Keros, a Lexington, MA pharma, is developing KER-050, to treat low blood cell counts, including anemia and thrombocytopenia, in patients with either myelodysplastic syndromes or myelofibrosis. Hansoh will be responsible for all KER-050 development in China, Hong Kong and Macau. It will make a $20 million upfront payment to Keros and pay up to $170.5 million in milestones plus royalties. More details....
Stock Symbols: (HK: 3692) (NSDQ: KROS)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.